2012.05.07 Weekly Broadcast Email
There were no updates made to the CCCWFU CCOP Research Base website for the week of May 7, 2012.
(A Randomized Phase II Dose Finding Study of ArginMax with or without Phosphodiesterase-5 Inhibitors for its Effect on Erectile Function and Quality of Life in Survivors of Prostate Cancer Previously Treated with Radiotherapy)
Announcement from study PI:
As a reminder, our dose finding study of ArginMax for prostate cancer survivors treated with radiotherapy remains open for accrual. To date, we have accrued 90 + patients of a planned 140 averaging nearly 6 patients per month. We appreciate the robust accrual to date and overall support of this study. During the past months, we have noticed a slight dip in accrual. We encourage all sites to continue either their excellent accrual or consider opening this study. With your continued robust support, we are likely to finish this study in about 1 more year. If there are questions regarding accrual please do not hesitate to contact me or the study team.
James J. Urbanic, M.D.